Patent EP0270340A2 successfully refreshed from Google Patents.
EP0270340A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of an antibody conjugate for the detection of necrotic malignant tissue and for the associated therapy
Assignee: Cancer Biologics Inc
•
Filing: 1987-12-01
•
Granted: —
•
Expires: 2007-12-01
Abstract
Abstract Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods.
Inventors
- 👤 Alan L. Epstein
- 👤 Clive R. Taylor
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 22:20
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3061; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K49/00; A61K49/04; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K51/1045; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5758; G01N33/57595; A61K2121/00; A61K2123/00; C07K2317/00; C07K2317/50; C07K2317/54
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
77 words
A method for preparing an antibody conjugate, comprising the steps of: obtaining a monoclonal antibody to an insoluble intracellular antigen present in neoplastic and normal cells, but not present on the exterior of a living cell, said antibody thus being specific to necrotic tissue not to living tissue; and conjugating said antibody to a material selected form an alpha-emitting radionuclide, a beta-emitting radionuclide, a radiopaque material, an antineoplastic agent, an immunotherapeutic agent, or a biological response modifier.
Claim 2
Independent Claim
77 words
A method for preparing an antibody conjugate, comprising the steps of: obtaining a monoclonal antibody to an insoluble intracellular antigen present in neoplastic and normal cells, but not present on the exterior of a living cell, said antibody thus being specific to necrotic tissue not to living tissue; and conjugating said antibody to a material selected form an alpha-emitting radionuclide, a beta-emitting radionuclide, a radiopaque material, an antineoplastic agent, an immunotherapeutic agent, or a biological response modifier.
Claim 3
Dependent Claim
12 words
The method of Claim 1, wherein said material is an antineoplastic agent.
Claim 4
Dependent Claim
11 words
A method of Claim 1, wherein said material is a radionuclide.
Claim 5
Independent Claim
20 words
The method of any of Claims 1-3, further comprising the step of combining the conjugate with an injectable pharmaceutical carrier.
Claim 6
Dependent Claim
67 words
A monoclonal antibody to an insoluble intracellular antigen present in neoplastic and normal cells, but not present on the exterior of a living cell, said antibody thus being specific to necrotic tissue but not to living tissue, wherein said antibody is conjugated to a material selected from an alpha-emitting radionuclide, a beta-emitting radionuclide, a radiopaque material, an antineoplastic agent, an immunotherapeutic agent, or a biological response modifier.
Claim 7
Dependent Claim
67 words
A monoclonal antibody to an insoluble intracellular antigen present in neoplastic and normal cells, but not present on the exterior of a living cell, said antibody thus being specific to necrotic tissue but not to living tissue, wherein said antibody is conjugated to a material selected from an alpha-emitting radionuclide, a beta-emitting radionuclide, a radiopaque material, an antineoplastic agent, an immunotherapeutic agent, or a biological response modifier.
Claim 8
Dependent Claim
13 words
The antibody of Claim 5, wherein said antibody is conjugated to a radionuclide.
Claim 9
Dependent Claim
14 words
The antibody of Claim 5, wherein said antibody is conjugated to a radiopaque material.
Claim 10
Dependent Claim
22 words
The antibody of Claim 5, wherein said antibody is conjugated to an antineoplastic agent, an immunotherapeutic agent, or a biological response modifier.
Claim 11
Dependent Claim
14 words
The antibody of any of Claims 5-8, in combination with an injectable pharmaceutical carrier.
Claim 12
Dependent Claim
31 words
Use of the antibody conjugate of Claim 6 or 7 for imaging neoplastic tissue in vivo in a mammal that has received therapy intended to kill malignant cells in said mammal.
Claim 13
Dependent Claim
36 words
Use of the antibody conjugate of Claim 6 or 7 in the preparation of a medicament for imaging neoplastic tissue in vivo a mammal that has received therapy intended to kill malignant cells in said mammal.
Claim 14
Dependent Claim
12 words
Use of the antibody conjugate of Claim 8 in treating neoplastic disease.
Claim 15
Dependent Claim
31 words
Use of the antibody-antineoplastic agent conjugate of Claim 8 in the preparation of a medicament for enhancing in a mammal the effects of therapy that kills malignant cells in vivo .
Claim 16
Dependent Claim
40 words
A use as claimed in Claim 12 or 13, wherein said antineoplastic agent comprises at least one of a cytotoxic agent, a toxin, a biological response modifier, a radiosensitizing compound, and alpha-emitting radionuclide, a beta-emitting radionuclide, and an antiproliferative agent.
Claim 17
Dependent Claim
11 words
A conjugate made in accordance with any one of Claims 1-4.
Claim 18
Independent Claim
116 words
A method for measuring effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of: obtaining monoclonal antibody that is specific to an insoluble internal cellular component of both normal and malignant cells of said mammal but not to external cellular components, said monoclonal antibody being labeled; contacting said labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo , thereby permitting said antibody to bind preferentially to said insoluble internal cellular component of cells that have been killed by said therapy; and determining the effectiveness of said therapy by measuring the binding of said labeled antibody to said insoluble internal cellular component.
Claim 19
Independent Claim
116 words
A method for measuring effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of: obtaining monoclonal antibody that is specific to an insoluble internal cellular component of both normal and malignant cells of said mammal but not to external cellular components, said monoclonal antibody being labeled; contacting said labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo , thereby permitting said antibody to bind preferentially to said insoluble internal cellular component of cells that have been killed by said therapy; and determining the effectiveness of said therapy by measuring the binding of said labeled antibody to said insoluble internal cellular component.
Claim 20
Dependent Claim
13 words
The method of Claim 16, wherein said contacting step occurs in vitro .
Claim 21
Dependent Claim
13 words
The method of Claim 16, wherein said contacting steps occurs in vivo .
Claim 22
Dependent Claim
11 words
The method of Claim 18, wherein said label is a radionuclide.
Claim 23
Dependent Claim
12 words
The method of Claim 18, wherein said label is a radiopaque material.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.